In focus
Latest feed
Trump Extends Most‑Favored‑Nation Drug Pricing to Every State Medicaid Program
FDA Approves AstraZeneca’s New Breast‑Cancer Therapy Amid Access Hurdles
Rare‑Disease Biotechs Push Back on Trump’s Price‑Cut Push While PBMs Slip Around State Laws
Rare Disease Makers Push Back on Medicare Price‑Cut Pilots
